GEN Exclusives

More »

GEN News Highlights

More »
Jul 2, 2009

J&J to Initially Spend $1.5B for Elan’s Alzheimer’s Immunotherapy Program

  • Johnson & Johnson is acquiring substantially all Elan’s assets and rights related to the Alzheimer's immunotherapy program (AIP program) through a newly formed company. JnJ will invest $1 billion in Elan in exchange for newly issued American depositary receipts of Elan, representing 18.4% of Elan's outstanding ordinary shares.

    The new JnJ entity will take over Elan's responsibilities under its collaboration with Wyeth and will initially commit up to $500 million. Upon closing, the transaction will have an estimated dilutive impact of $0.02 to $0.03 on JnJ’s 2009 adjusted earnings per share.

    In consideration for the transfer of these rights and assets, Elan will receive a 49.9% equity interest in the newly formed JnJ company. Elan will be entitled to a 49.9% share of the profits and certain royalties.

    The AIP program represents Elan's interest in a collaboration with Wyeth to research, develop, and commercialize selected products for the treatment and/or prevention of neurodegenerative conditions including Alzheimer's disease.

    The lead compound in the AIP program, bapineuzumab administered intravenously once every three months, is in Phase III clinical trials. A subcutaneous formulation, administered once a week is in Phase II studies. In addition, a vaccine for Alzheimer's disease (ACC-001) is also under development.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?